The effect of ouabain on exocytotic and nonexocytotic norepinephrine release was investigated in perfused rat and guinea pig hearts. The overflow of endogenous norepinephrine and its neuronal metabolite 3,4-dihydroxyphenylethyleneglycol (DOPEG) was determined by highpressure liquid chromatography. DOPEG served as the indicator of free axoplasmic norepinephrine concentrations. The overflow of the norepinephrine cotransmitter neuropeptide Y (NPY) was determined by radioimmunoassay and NPY was used as marker for exocytotic release. Electrical stimulation of the left stellate ganglion resulted in exocytotic norepinephrine release in rat and guinea pig hearts. Ouabain caused an increase in stimulation-induced norepinephrine overflow from rat and guinea pig hearts by 40%. However, overflow of NPY was decreased by 40%, indicating a reduced exocytosis rate. Ouabain increased both norepinephrine and NPY overflow, suggesting enhancement of exocytosis, when neuronal catecholamine uptake (uptake,) was blocked by desipramine or when presynaptic a2-adrenoceptors were inhibited by yohimbine. The results demonstrate an interaction of ouabain with both calciumdependent exocytosis and uptake1 of norepinephrine. Under calcium-free conditions, ouabain or potassium-free perfusate resulted in norepinephrine release from hearts when the axoplasmic norepinephrine concentration was elevated by the reserpinelike agent Ro 4-1284. This release was independent from neural activity, not accompanied by NPY overflow, and suppressed by the uptake1 blocker desipramine. These findings are in keeping with carriermediated nonexocytotic norepinephrine release that is caused by reversal of the transport direction of the uptake1 carrier. During myocardial ischemia nonexocytotic norepinephrine release was accelerated and enhanced by inhibition of Na+,K+-ATPase before ischemia. This study demonstrates the potential of digitalis glycosides to interact both with transmitter exocytosis and with the neuronal catecholamine transport system by Na+,K+-ATPase inhibition. Interaction with the catecholamine transport system involves both inhibition of norepinephrine inward transport and induction of norepinephrine outward transport, resulting in nonexocytotic norepinephrine release. (Circulation Research 1991;68:1628-1637 F acilitation by cardiac glycosides of norepinephrine release from sympathetic nerve endings is well documented (for review, see Reference 1). In part, the cardiovascular effects of digitalis glycosides have been attributed to their ability to increase both spontaneous and nerve stimulationinduced norepinephrine overflow by inhibition of Na+,K+-ATPase (for review, see Reference 2). However, contradictory data have been published concerning mechanisms of this facilitation of norepi- 
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The effect of ouabain on exocytotic and nonexocytotic norepinephrine release was investigated in perfused rat and guinea pig hearts. The overflow of endogenous norepinephrine and its neuronal metabolite 3,4-dihydroxyphenylethyleneglycol (DOPEG) was determined by highpressure liquid chromatography. DOPEG served as the indicator of free axoplasmic norepinephrine concentrations. The overflow of the norepinephrine cotransmitter neuropeptide Y (NPY) was determined by radioimmunoassay and NPY was used as marker for exocytotic release. Electrical stimulation of the left stellate ganglion resulted in exocytotic norepinephrine release in rat and guinea pig hearts. Ouabain caused an increase in stimulation-induced norepinephrine overflow from rat and guinea pig hearts by 40%. However, overflow of NPY was decreased by 40%, indicating a reduced exocytosis rate. Ouabain increased both norepinephrine and NPY overflow, suggesting enhancement of exocytosis, when neuronal catecholamine uptake (uptake,) was blocked by desipramine or when presynaptic a2-adrenoceptors were inhibited by yohimbine. The results demonstrate an interaction of ouabain with both calciumdependent exocytosis and uptake1 of norepinephrine. Under calcium-free conditions, ouabain or potassium-free perfusate resulted in norepinephrine release from hearts when the axoplasmic norepinephrine concentration was elevated by the reserpinelike agent Ro 4-1284. This release was independent from neural activity, not accompanied by NPY overflow, and suppressed by the uptake1 blocker desipramine. These findings are in keeping with carriermediated nonexocytotic norepinephrine release that is caused by reversal of the transport direction of the uptake1 carrier. During myocardial ischemia nonexocytotic norepinephrine release was accelerated and enhanced by inhibition of Na+,K+-ATPase before ischemia. This study demonstrates the potential of digitalis glycosides to interact both with transmitter exocytosis and with the neuronal catecholamine transport system by Na+,K+-ATPase inhibition. Interaction with the catecholamine transport system involves both inhibition of norepinephrine inward transport and induction of norepinephrine outward transport, resulting in nonexocytotic norepinephrine release. (Circulation Research 1991; 68:1628 -1637 F acilitation by cardiac glycosides of norepinephrine release from sympathetic nerve endings is well documented (for review, see Reference 1). In part, the cardiovascular effects of digitalis glycosides have been attributed to their ability to increase both spontaneous and nerve stimulationinduced norepinephrine overflow by inhibition of Na+,K+-ATPase (for review, see Reference 2) . However, contradictory data have been published concerning mechanisms of this facilitation of norepi-um-independent processes involved in the extracellular accumulation of norepinephrine in the heart. The effect of ouabain on calcium-dependent exocytotic norepinephrine release induced by electrical stimulation of the stellate ganglion was studied in rat and guinea pig hearts that were perfused in situ with intact sympathetic innervation.8,9 Calcium-independent nonexocytotic norepinephrine release was examined in isolated perfused hearts of either species. This type of release has been demonstrated to occur independent from central sympathetic activity and to gain relevance during myocardial ischemia. 10 Endogenous norepinephrine was measured to avoid problems resulting from loading sympathetic nerve endings with labeled exogenous transmitters such as an inhomogeneous distribution of ['H]norepinephrine within the tissue and within the sympathetic nerve terminal.11 NPY, which is stored with norepinephrine in sympathetic neurons,12 has been demonstrated to be coreleased with norepinephrine in guinea pig hearts during exocytotic transmitter release9 but not with nonexocytotic, carrier-mediated efflux during anoxia13 and ischemia.14 Thus, in this study NPY was used as a marker for norepinephrine exocytosis in guinea pig hearts. In rat hearts neuronal NPY content and release were too low to be used for this purpose.
DOPEG, the main norepinephrine metabolite arising from deamination of axoplasmic norepinephrine by monoamine oxidase, is diffusible across the neuronal cell membrane and served as an indicator for free axoplasmic norepinephrine concentrations.15 '16 In the present study, overflow of DOPEG from hearts was measured to define conditions for nonexocytotic norepinephrine release induced by cardiac glycosides.
Materials and Methods
Male Wistar rats (180-220 g; Ivanovas, Kislegg, FRG) or male guinea pigs (250-300 g; Thomae, Biberach, FRG) were anesthetized with thiobutabarbital (50 mg/kg i.p.). In all study protocols the hearts were perfused at a constant flow of 4 ml/min (rats) or 7 ml/min (guinea pigs). The catecholamine samples were stabilized by the addition of Na2EDTA (10 mM) and the NPY samples by adding phosphate buffer containing 3% bovine serum albumin. All samples were stored at -60°C until assayed.
Endogenous norepinephrine and DOPEG were measured by using a high-pressure liquid chromatography (HPLC) method as described by Schomig et al. 16 After a two-step extraction, separation was performed with a reversed-phase counterion HPLC system. Electrochemical detection was used for quantitative analysis. Recovery was 98% for norepinephrine and 92% for DOPEG, the limits of detection were 0.1 and 0.2 nmol/l, and the coefficients of variation were 5.9% and 5.8%, respectively.
A specific radioimmunoassay was used to measure endogenous NPY. 9 The sensitivity of the radioimmunoassay (i.e., the amount of the peptide that displaced 10% of the label) was 0.7 fmol/tube. The 50% intercept was 4.0 fmol/tube. With routine radioimmunoassay there was an intra-assay variation of 15% and an interassay variation of 17%.
Agents Used
The following agents were used: desipramine hydrochloride (CIBA-GEIGY, Basel, Switzerland), ouabain (Merck, Darmstadt, FRG), Ro 4-1284 (2-hydroxy-2-ethyl-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-1 lb-H-benzo[a]-quinolizine; Hoffmann-La Roche, Basel, Switzerland), and yohimbine hydrochloride (Sigma Chemical Co., Munich). None of the drugs used in the experiments had any influence on the perfusion flow or interfered with extraction, separation, and detection of norepinephrine and DOPEG, or with radioimmunoassay of NPY.
Statistical Methods
Results are expressed as the arithmetic mean for data and as the geometric mean for SJS, ratios.
Statistical differences were tested with Student's t test for paired data. If S, and S2 were different in control experiments, the statistical difference between the control and intervention groups was tested by using Student's t test for unpaired data. A value of p <0.05 was considered significant.
Results
The influence of ouabain on exocytotic norepinephrine release was examined in hearts perfused in situ with intact sympathetic innervation in the presence of extracellular calcium. In this preparation cardiac sympathetic fibers were stimulated electrically.
Interaction of ouabain with nonexocytotic release was investigated in isolated perfused hearts in the absence of extracellular calcium to avoid exocytotic release. No electrical stimulation of sympathetic nerves was performed. (Figure 2 ). This dissociation of norepinephrine and NPY overflow induced by uptake blockade had been demonstrated to be a consequence of elevated intrasynaptic norepinephrine concentrations that result in a suppression of the transmitter exocytosis rate through activation of presynaptic inhibitory a2-adrenoceptors.9
To test the hypothesis that the suppression of NPY overflow by ouabain was due to a similar mode of action the following effects of ouabain were investigated in the guinea pig heart: 1) the effect of ouabain on stimulation-induced norepinephrine overflow after blockade of presynaptic a2-adrenoceptors by yohimbine, 2) the effect of ouabain on stimulation-induced norepinephrine and NPY overflow after blockade of uptake1 by desipramine, and 3) the influence of ouabain on uptake1.
Although blockade of presynaptic a2-adrenoceptors by 1 gM yohimbine before S2 resulted in an increased overflow of both norepinephrine (SJS1, 1.47) and NPY (SJS1, 1.77) (data from Reference 9), demonstrating interruption of presynaptic a2-mediated autoinhibition (Figure 2) , administration of yohimbine (Figure 3 ). Control experiments with two periods of stimulation after blockade of uptake1 by 300 nM desipramine demonstrated good comparability of norepinephrine overflow in the rat (S2/S1, 0.95; n=10) and of norepinephrine (S2/S1, 0.81; n=7) and NPY overflow (S2/S1, 1.11; n=7) in the guinea pig. Ouabain before S2 still increased stimulation-induced norepinephrine overflow (rat: S2/S1, 1.24; n=7; guinea pig: S2/S1, 1.38; n=9;p<0.05) (Figures 1 and 3) . However, in contrast to the experiments without additional uptake blockade, ouabain induced an increase in NPY overflow from guinea pig hearts (S2/S1, 1.48; n=9; p<0.05) (Figure 3 To verify whether the effect of ouabain was due to Na',K+-ATPase inhibition, the sodium pump was inhibited by omission of potassium from the perfusate. Potassium-free perfusion combined with Ro 4-1284 elicited an increased norepinephrine overflow that was accompanied by a decreased DOPEG overflow. Again, norepinephrine overflow was reduced by about 80% when uptake, was blocked by desipramine ( Figure 4 ). These effects on norepinephrine overflow of suppressed Na+,K+-ATPase were reversible: restitution of Na+,K+-ATPase activity by increasing potassium from 0 to 4 mM abolished norepinephrine overflow within 5 minutes, whereas DOPEG overflow increased ( Figure 5 ).
To investigate whether carrier-mediated nonexocytotic norepinephrine release occurring during myocardial ischemia10 is influenced by Na+,K'-ATPase inhibition, ischemia-induced norepinephrine release from rat hearts was determined in the absence and presence of ouabain. (Figure 6 ). Discussion In the present study the effects of ouabain on extracellular norepinephrine accumulation have been investigated in perfused rat and guinea pig hearts and have been related to exocytotic and nonexocytotic processes by using the overflow of NPY and DOPEG as tools for discrimination between two different release mechanisms (Figure 7 ). Norepinephrine overflow caused by exocytosis, the principal way of norepinephrine release under physiological conditions, was enhanced mainly by inhibition of catecholamine elimination via neuronal uptake. The additional potential of cardiac glycosides to enhance exocytosis rate was masked by effective presynaptic autoinhibition. On the other hand, digitalis glycosides induced and accelerated nonexocytotic carrier-mediated norepinephrine release, which may gain relevance during myocardial ischemia. 
Enhancement of Extracellular Norepinephrine Accumulation Caused by Exocytosis
Ouabain enhanced norepinephrine overflow after left stellate ganglion stimulation both from rat and guinea pig hearts and led to a parallel increase in NPY overflow from guinea pig hearts when either uptake1 was blocked by desipramine or presynaptic autoinhibition was prevented by yohimbine. A corelease of NPY with norepinephrine has been shown to occur exclusively during exocytotic transmitter release.13 With inactive uptake, or blocked presynaptic autoinhibition, therefore, ouabain enhanced norepinephrine overflow from the heart through an increase in exocytosis rate. Since exocytosis is a calcium-mediated process,22,23 this increase is most likely due to improved intracellular calcium availability subsequent to an increase of axoplasmic sodium. 24, 25 There are various theories about the mechanism of increased axoplasmic calcium concentrations after Na',K+-ATPase inhibition, such as augmented calcium entry, reduced calcium extrusion from the cell, or displacement of calcium from intracellular storage sites.24,26,27 However, an increased exocytosis rate was not the predominant way by which ouabain exerted its enhancing action on stimulation-induced norepineph-
With active autoinhibition through presynaptic a2-receptors and a primarily intact uptake1 system, ouabain increased extracellular norepinephrine accumulation by a mode of action different from augmentation of exocytosis rate. In fact, exocytosis rate was even suppressed by ouabain. This was indicated by the marked reduction of NPY overflow after nerve stimulation in the presence of ouabain.
Suppression of exocytosis rate was mediated by autoinhibition, and blockade of presynaptic autoinhibition by yohimbine resulted in a ouabain-induced increase of both norepinephrine and NPY overflow during electrical stimulation, indicating increased exocytosis. The results suggest ongoing control of exocytosis by autoinhibition even in the presence of enhanced intracellular sodium.
High concentrations of yohimbine (IC50 approximately 10 ,uM) have been described to inhibit norepinephrine overflow evoked by acetylstrophanthidin in the absence of sympathetic stimulation.28 These effects can be neither excluded nor substantiated in our experimental model with lower yohimbine concentrations (1 gM) and electrical stimulation to induce release of the neurotransmitters.
A similar dissociation between norepinephrine and NPY overflow as seen with ouabain was found when desipramine was administered (Figure 2 ). This effect of desipramine on stimulation-induced norepineph-NONEXOCYTOTIC iBAIN RELEASE NA DOPEG FIGURE 7. Scheme of mechanisms leading to extracellular norepinephrine (NA) accumulation after Na',K4-ATPase inhibition by ouabain. Norepinephrine accumulation caused by transmitter exocytosis (left) is affected both by increased exocytosis rate and reduced norepinephrine reuptake into the nerve ending via neuronal catecholamine uptake (uptake,). Both mechanisms are influenced by an increase in axoplasmic sodium after Na ',K+-A TPase inhibition. Exocytosis rate, which is reflected by the overflow of neuropeptide Y (NPY), is enhanced by augmentation of intracellular calcium availability leading to an improved excitation-secretion coupling. Norepinephrine reuptake is diminished by reduction of the transmembrane sodium gradient. Similarly, ouabain increased stimulation-induced norepinephrine overflow by inhibition of uptake1. The expected potentiation of exocytosis by ouabain was masked by effective presynaptic autoinhibition secondary to norepinephrine accumulation within the synaptic cleft caused by uptake blockade ( Figure  7 ). In the presence of uptake blockade by desipramine the effect of ouabain on uptake1 was eliminated and the effect on exocytosis was unmasked. Nerve stimulation resulted in a relative increase of exocytosis rate indicated by the enhanced overflow of both norepinephrine and NPY. Inhibition by ouabain of uptake15,31 was confirmed for the experimental model of the perfused guinea pig heart by measuring [3H]norepinephrine extraction. The results are in accordance with the close relation between Na+,K+-ATPase inhibition and suppression of uptake1 by ouabain that had been demonstrated for various species and tissues.32 There was an important difference between the kinetics of uptake inhibition by ouabain compared with that by desipramine. This finding reflects the different modes of action of both substances. Desipramine binds to the norepinephrine binding site of the uptake1 carrier33, 34 and inhibits amine transport in both directions. Uptake inhibition by cardiac glycosides is thought to be a consequence of increased axoplasmic sodium concentrations.3' The inhibitory action of augmented axoplasmic sodium on catecholamine uptake can be derived from the role of the transmembrane sodium gradient for norepinephrine transport3536: For energy, the cotransport of norepinephrine and sodium depends on the transmembrane sodium gradient, which is maintained by Na+,K+-ATPase. The physiological high transmembrane sodium gradient directed from outside to inside facilitates movement of norepinephrine from the extracellular space to the axoplasm. Since pump inhibition by cardiac glycosides involves a rise in axoplasmic sodium, reuptake of extracellular norepinephrine on the one hand is hampered. On the other hand, movement of norepinephrine from the axoplasm to the extracellular space is facilitated by reversal of the transport direction of the carrier.
Induction of Carier-Mediated Nonexocytotic
Norepinephrine Release
This reversal of transport direction of the neuronal catecholamine carrier results in a calcium-independent efflux of norepinephrine when axoplasmic norepinephrine concentrations are increased. Such nonexocytotic release has been described for various pharmacological and pathophysiological conditions.7,10,15"16,37,38 Overflow of endogenous norepinephrine after Na+,K+-ATPase inhibition by either ouabain or potassium-free perfusion occurred when axoplasmic norepinephrine was elevated by reserpinelike agents such as Ro 4-1284 or trimethyltin. 37 The rise in axoplasmic norepinephrine was indicated by a marked overflow of DOPEG after inhibition of vesicular norepinephrine uptake by Ro 4-1284 or blockade of vesicular H+-ATPase by trimethyltin. 39 This type of cardiac norepinephrine release was found in the absence of extracellular calcium, not accompanied by NPY overflow and suppressed by the uptake1 inhibitor desipramine, suggesting norepinephrine efflux across the neuronal plasma membrane with the uptake, carrier in reverse of its usual transport direction. Induction by ouabain of carrier-mediated release of endogenous norepinephrine from the axoplasma is in keeping with the finding of calciumindependent release of 3H or ['H]norepinephrine after Na+,K+-ATPase inhibition from sympathetic nerve endings loaded with labeled norepinephrine.7"15 '38 Because the Na+,K+-ATPase of the rat is particularly insensitive to cardiac glycosides,40 high concentrations of ouabain were necessary to induce nonexocytotic norepinephrine release from rat hearts. Ancillary properties of cardiac glycosides were excluded by Na+,K+-ATPase inhibition by potassiumfree perfusion, which had effects on norepinephrine overflow comparable to those of ouabain. Moreover, norepinephrine efflux was completely suppressed when Na+,K+-ATPase was reactivated by the addition of potassium. These data emphasize the functional link between axoplasmic sodium concentration and transmembrane norepinephrine transport.
Nonexocytotic release has been demonstrated to be the predominant mechanism of extracellular norepinephrine accumulation during myocardial energy deficiency.10'41'42 Ischemia-induced norepinephrine release is assumed to occur in two steps. First, norepinephrine is lost from its storage vesicles as a consequence of impaired energy supply and accumulates in the axoplasma. 16 In a second, rate-limiting step free axoplasmic norepinephrine is transported into the extracellular space by the uptake1 carrier in reverse of its usual transport direction16 as a consequence of increased axoplasmic sodium concentrations. 37 In this study, Na+-K+ pump inhibition before myocardial ischemia accelerated the time course of ischemia-induced norepinephrine overflow. On the other hand, desipramine was able to suppress norepinephrine overflow during ischemia almost completely. This differential effect of ouabain and desipramine is due to their different modes of interaction with the neuronal catecholamine carrier. Desipramine acts by direct binding to the uptake, carrier and blocks both inward and outward transport, whereas digitalis glycosides affect norepinephrine transport indirectly through an increase of axoplasmic sodium concentrations. Therefore, by induction of nonexocytotic norepinephrine release, cardiac glycosides have the potency to act like indirect sympathomimetic agents during myocardial ischemia. Lorenz On the other hand, in a preparation with an unimpaired energy state and low axoplasmic norepinephrine concentrations, reflected by the absence of substantial DOPEG liberation, no major norepinephrine release could be induced by Na+,K+-ATPase inhibition (Figures 4 and 5) . From these data, it may be concluded that nonexocytotic norepinephrine release induced by digitalis glycosides in addition requires leakage of norepinephrine from neuronal storage vesicles caused either by pharmacological agents or by energy deficiency of the sympathetic neuron.
